Rethinking the burden of latent tuberculosis to reprioritize research
Nat Microbiol
.
2024 May;9(5):1157-1158.
doi: 10.1038/s41564-024-01683-0.
Authors
Marcel A Behr
1
,
Paul H Edelstein
2
3
,
Lalita Ramakrishnan
4
5
Affiliations
1
Department of Medicine, McGill University, McGill International TB Centre, Montreal, Quebec, Canada.
2
Department of Medicine, University of Cambridge, Cambridge, UK.
3
MRC Laboratory of Molecular Biology, Cambridge, UK.
4
Department of Medicine, University of Cambridge, Cambridge, UK. lalitar@mrc-lmb.cam.ac.uk.
5
MRC Laboratory of Molecular Biology, Cambridge, UK. lalitar@mrc-lmb.cam.ac.uk.
PMID:
38671272
DOI:
10.1038/s41564-024-01683-0
No abstract available
MeSH terms
Biomedical Research
Cost of Illness
Humans
Latent Tuberculosis* / drug therapy
Latent Tuberculosis* / epidemiology
Mycobacterium tuberculosis / genetics